CareDx unveils IPO plans; U.S. remote radiology imaging initiative hits Russia;

> Molecular diagnostics company CareDx will pursue an IPO for up to $50 million to fuel the use of next-generation sequencing in new blood tests that monitor heart transplant biomarkers. Story

> Quest Diagnostics ($DGX) said it will offer two of BioMérieux's BRAF mutation companion diagnostics for two of GlaxoSmithKline's ($GSK) melanoma drugs. Story (reg. req.)

> A year after the U.S. Supreme Court ended Myriad Genetics' ($MYGN) legal monopoly on breast-cancer gene testing, efforts to advance more breast cancer gene variants into public databases are accelerating. Story

> A new MRI technique could quicken the diagnosis of traumatic brain injury. Story

> Virtual Radiologic (vRad), a U.S.-based telemedicine and radiology practice, and Ramsay Diagnostics, a network of imaging centers in St. Petersburg and Moscow, will partner to bring U.S. remote radiology imaging services to the Russian market. Release

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.